RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of VRDN
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Viridian Therapeutics, Inc. stock price ended at $17.51 on Wednesday, after gaining 0.81%.
(Updated on Mar 27, 2024)

Sell candidate since Mar 22, 2024 Loss -2.78% PDF

The Viridian Therapeutics, Inc. stock price gained 0.81% on the last trading day (Wednesday, 27th Mar 2024), rising from $17.37 to $17.51. During the last trading day the stock fluctuated 5.13% from a day low at $17.14 to a day high of $18.02. The price has fallen in 6 of the last 10 days and is down by -1.68% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 78 thousand more shares were traded than the day before. In total, 681 thousand shares were bought and sold for approximately $11.92 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -19.37% during the next 3 months and, with a 90% probability hold a price between $13.28 and $15.89 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

VRDN Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, March 15, 2024, and so far it has risen 2.46%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Viridian Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $17.79 and $18.44. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Viridian Therapeutics, Inc. stock

Viridian Therapeutics, Inc. finds support from accumulated volume at $17.34 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.88 between high and low, or 5.13%. For the last week, the stock has had daily average volatility of 5.44%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (VRDN) For The Upcoming Trading Day Of Thursday 28th

For the upcoming trading day on Thursday, 28th we expect Viridian Therapeutics, Inc. to open at $17.56, and during the day (based on 14 day Average True Range), to move between $16.37 and $18.65, which gives a possible trading interval of +/-$1.14 (+/-6.50%) up or down from last closing price. If Viridian Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 13.01% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $17.34 (0.97%) than the resistance at $18.78 (7.25%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Viridian Therapeutics, Inc. stock A Buy?

Viridian Therapeutics, Inc. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.433 Sell Candidate Unchanged

Predicted Opening Price for Viridian Therapeutics, Inc. of Thursday, March 28, 2024

Fair opening price March 28, 2024 Current price
$17.56 ( 0.267%) $17.51

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for VRDN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 18.44 5.29 %
R2 18.10 3.37 %
R1 17.89 2.19 %
Current price: 17.51
Support S1 17.22 -1.65 %
S2 17.01 -2.84 %
S3 16.68 -4.76 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 20.14 15.02 %
R2 19.89 13.59 %
R1 18.78 7.25 %
Current price 17.51
Support S1 17.34 -0.97%
S2 17.21 -1.71%
S3 17.09 -2.40%

FAQ

What is the symbol for Viridian Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Viridian Therapeutics, Inc. is VRDN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Viridian Therapeutics, Inc. Stock?
Viridian Therapeutics, Inc. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Viridian Therapeutics, Inc. Stock?
Viridian Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Viridian Therapeutics, Inc. Stock.

What's the current price of Viridian Therapeutics, Inc. Stock?
As of the end of day on the 2024-03-27, the price of an Viridian Therapeutics, Inc. (VRDN) share was $17.51.

What is the 52-week high and low for Viridian Therapeutics, Inc. Stock?
The 52-week high for Viridian Therapeutics, Inc. Stock is $30.08 and the 52-week low is $10.93.

What is the market capitalization of Viridian Therapeutics, Inc. Stock?
As of the 2024-03-27, the market capitalization of Viridian Therapeutics, Inc. is 1.099B.

When is the next earnings date for Viridian Therapeutics, Inc.?
The upcoming earnings date for Viridian Therapeutics, Inc. is May 14, 2024.
Click to get the best stock tips daily for free!

About Viridian Therapeutics, Inc.

Viridian Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ... VRDN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT